TrialMolecular oncology2015

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.

Nada Albarakati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.